Results 101 to 110 of about 12,791 (189)

Lipid‐based Nano‐delivery systems as a promising strategy for the treatment of epilepsy: Current status and challenges

Epilepsia Open, Volume 11, Issue 4, Page 1095-1110, August 2026.
Abstract Objective Epilepsy is a prevalent chronic neurological disorder characterized by abnormal neuronal electrical activity. The primary treatment modality for individuals with epilepsy (PWE) is antiseizure medication (ASM). The multiple potential factors contributing to treatment resistance in epilepsy may be attributed to the inability of ASMs to
Priya Kannan Varshini, Arunachalam Divya, Kumar Sowndharya, Parthiban Jeevitha, Selvam Manoj, Ashiq Rahman, Athil Ahamed, Ravichandiran Abirahul, Paranthaman Subash, Sulekha Khute   +9 more
wiley   +1 more source

Mitochondrial bioenergetic is impaired in Monocarboxylate transporter 1 deficiency: a new clinical case and review of the literature. [PDF]

Orphanet J Rare Dis, 2022
Stanescu S, Bravo-Alonso I, Belanger-Quintana A, Pérez B, Medina-Diaz M, Ruiz-Sala P, Flores NP, Buenache R, Arrieta F, Rodríguez-Pombo P.   +9 more
europepmc   +1 more source

Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
This review elucidates how lactylation, a novel histone modification driven by lactate, regulates colorectal cancer pathogenesis. We summarize its roles in tumor progression, metastasis, stemness, immunosuppression, and therapy resistance, and discusses the promising therapeutic strategies of targeting the lactylation pathway.
Shuilan Yao, Yun Liang, Xinwen Liang, Qisheng Su, Xiaohong Li   +4 more
wiley   +1 more source

Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma. [PDF]

Transl Cancer Res, 2021
Li Q, Xu B, Tang Y, Li Y, Ying H.
europepmc   +1 more source

The Dual Role of the Gut Microbiota in Cancer Chemoresistance

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Comparison between Microbiota and Cancer therapy. ABSTRACT Chemoresistance is one of the primary reasons that cancer chemotherapy fails to deliver successful treatment outcomes and contributes to poor overall survival rates for patients with cancer. New research has begun to shed light on the effects of the gut microbiome (GM).
Hamed Tahmasebi, Aisa Bahar, Meisam Khazaei, Mohammad Reza Arabestani   +3 more
wiley   +1 more source

Monocarboxylate transporter 1 is a novel target for breast cancer stem like-cell inhibition by diallyl trisulfide. [PDF]

Mol Carcinog, 2022
Kim SH, Singh SV.
europepmc   +1 more source

Monocarboxylate Transporter 1 Hyperinsulinism [PDF]

, 2020
openaire   +1 more source

Glucose Transporter 1 in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
As the quintessential facilitator of basal glucose uptake, glucose transporter 1 (GLUT1) is indispensable for maintaining systemic energy homeostasis. This graphical abstract delineates the multidimensional landscape of GLUT1 in normal physiology. It highlights its tissue‐specific metabolic roles—from fueling erythrocytes and fetal development to ...
Yi Tai, Zhihao Chen, Yuping Zhu, Weidong Han   +3 more
wiley   +1 more source

Monocarboxylate Transporter 1 May Benefit Cerebral Ischemia via Facilitating Lactate Transport From Glial Cells to Neurons. [PDF]

Front Neurol, 2022
Zhang M, Wang Y, Bai Y, Dai L, Guo H.
europepmc   +1 more source

MYC in Oncogenesis and Therapeutic Implications

MedComm, Volume 7, Issue 8, August 2026.
The MYC oncogene family (c‐MYC, N‐MYC, L‐MYC) functions as a central transcriptional hub orchestrating cancer progression through multiple interconnected pathways. This graphical abstract illustrates MYC's role as a multidimensional regulator positioned at the nexus of tumor microenvironment remodeling, metabolic reprogramming, and therapeutic ...
Na Zhang, Li Wei, Cuiping Tang, Peilong Lai, Wenbin Zhong, Hua You   +5 more
wiley   +1 more source